XML 106 R68.htm IDEA: XBRL DOCUMENT

Significant agreements - Summary of Contract Assets and Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Contract liabilities:
Beginning Balance	$ 135,194,000	$ 61,873,000
Additions	3,386,000	95,960,000
Deductions	(35,275,000)	(26,976,000)
Impact of Exchange Rates	(1,647,000)	4,337,000
Ending Balance	101,658,000	135,194,000
Contract assets
Contract assets	0	0
Bayer collaboration deferred revenue
Contract liabilities:
Beginning Balance	43,618,000
Additions	296,000	45,000,000
Deductions	(3,393,000)	(1,160,000)
Impact of Exchange Rates	(561,000)	(222,000)
Ending Balance	39,960,000	43,618,000
Bayer collaboration deferred revenue \| Deferred revenue material rights option
Contract liabilities:
Ending Balance	31,900,000
Novartis collaboration deferred revenue
Contract liabilities:
Beginning Balance	50,008,000
Additions	3,000,000	50,000,000
Deductions	(8,161,000)	(1,909,000)
Impact of Exchange Rates	(774,000)	1,917,000
Ending Balance	44,073,000	50,008,000
Novartis collaboration deferred revenue \| Deferred revenue material rights option
Contract liabilities:
Ending Balance	32,000,000
Ionis collaboration deferred revenue
Contract liabilities:
Beginning Balance	12,464,000	21,489,000
Additions	90,000	960,000
Deductions	(8,881,000)	(10,734,000)
Impact of Exchange Rates	(86,000)	749,000
Ending Balance	3,587,000	12,464,000
Ionis collaboration deferred revenue \| Deferred revenue material rights option
Contract liabilities:
Ending Balance	3,600,000
Genentech collaboration deferred revenue
Contract liabilities:
Beginning Balance	29,104,000	39,308,000
Deductions	(14,840,000)	(11,969,000)
Impact of Exchange Rates	(226,000)	1,765,000
Ending Balance	14,038,000	29,104,000
Genentech collaboration deferred revenue \| Deferred revenue material rights option
Contract liabilities:
Ending Balance	$ 13,500,000
AstraZeneca collaboration deferred revenue
Contract liabilities:
Beginning Balance		1,076,000
Deductions		(1,204,000)
Impact of Exchange Rates		$ 128,000